DEA's notice of proposed rulemaking (Docket DEA1715) to place 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT in Schedule I, with comments due October 23, 2026.
Comments on the Drug Enforcement Administration (DEA) Schedule I tryptamines proposal are due on or before October 23, 2026, under Docket No. DEA1715 at regulations.gov. The notice of proposed rulemaking would place five tryptamine hallucinogens in Schedule I of the Controlled Substances Act (CSA). That would bring DEA registration requirements and Schedule I sanctions to anyone who handles them, including researchers.
The notice is document 2026-19400 in the Federal Register, with publication scheduled for September 23, 2026. The five substances are 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT.
Comments on Docket No. DEA1715 must be submitted electronically or postmarked on or before October 23, 2026. The notice sets the deadline at 30 days after Federal Register publication, and publication was scheduled for September 23, 2026, so September 23 plus 30 days gives October 23. The Federal Docket Management System stops accepting electronic comments at 11:59 p.m. Eastern Time on that last day.
To file electronically, use the Federal eRulemaking Portal at regulations.gov and search for Docket No. DEA1715. Put "Docket No. DEA1715" on everything you send, whether electronic or on paper. A summary of the proposed rule is posted in the same docket, and the full notice is available as a public-inspection PDF.
Paper comments go by mail to Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DEA discourages paper comments that duplicate an electronic submission, so pick one route for each comment. A paper comment counts if it is postmarked on or before October 23, 2026.
A request for a hearing, or for a waiver of one, follows a separate route under 21 Code of Federal Regulations (CFR) 1308.44, 1316.47 and 1316.49. Hearing requests go to the DEA Administrator at 8701 Morrissette Drive, Springfield, Virginia 22152. The notice says hearing requests must be received by the 30-day date, while paper comments only need a postmark by then, so mail a hearing request early enough to arrive by October 23, 2026.
Questions about the notice go to Dr. Terrence L. Boos of the Drug and Chemical Evaluation Section, Diversion Control Division, DEA, who is listed as the contact in the Federal Register notice. Confirm the deadline and docket number on regulations.gov before you file.
DEA's proposed rule would place five tryptamine hallucinogens in Schedule I of the CSA, including their salts, isomers and salts of isomers whenever possible. The Department of Justice and DEA filed it under 21 CFR Part 1308. Its title lists each substance by full chemical name and abbreviation.
4-OH-DiPT is 4-hydroxy-N,N-diisopropyltryptamine, and 5-MeO-AMT is 5-methoxy-alpha-methyltryptamine. 5-MeO-MiPT is 5-methoxy-N-methyl-N-isopropyltryptamine. 5-MeO-DET is 5-methoxy-N,N-diethyltryptamine, and DiPT is N,N-diisopropyltryptamine.
The notice uses the phrase "if finalized." It means the Schedule I controls would apply only after DEA publishes a final rule. At the proposal stage, the legal status of the five substances does not change.
None of the five is psilocybin, MDMA, ketamine, DMT or 5-MeO-DMT, and the notice proposes no change for any of those. 5-MeO-DET and 5-MeO-MiPT are not 5-MeO-DMT. Readers looking for those substances can see the DMT guide and the 5-MeO-DMT guide.
If DEA finalizes the proposal, anyone who handles or wants to handle the five substances would need DEA registration. The notice cites 21 United States Code (U.S.C.) 822, 823, 957 and 958, along with 21 CFR parts 1301 and 1312. Handling covers manufacture, distribution, reverse distribution, import, export, research, instructional activities, chemical analysis and possession.
A person who handles any of the five today and is not registered for Schedule I research would have to apply for registration. That person could not continue handling the substances unless DEA approves the application.
Researchers already registered for another Schedule I substance get a transition under 21 U.S.C. 822(h). A person already conducting research on the five may continue if they submit a completed application or modification no later than 90 calendar days after the final rule takes effect. That permission lasts until the person withdraws the application or DEA serves an order to show cause proposing denial.
Handlers would also face the administrative, civil and criminal sanctions that apply to other Schedule I substances. The notice applies these sanctions to the same list of activities that triggers registration.
DEA bases the proposal on evaluations from the Department of Health and Human Services (HHS), first delivered in 2012 and updated on April 2, 2026. DEA sent HHS a data review on December 19, 2008. HHS answered with scientific and medical evaluations and scheduling recommendations on March 29, May 17 and August 14, 2012, recommending Schedule I.
The April 2, 2026 update again recommended Schedule I for all five substances. DEA's three proposed findings are a high potential for abuse similar to Schedule I hallucinogens, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.
On medical use, HHS states that none of the five has Food and Drug Administration (FDA) approval for any therapeutic indication. HHS also reports no adequate and well-controlled clinical studies and no well-defined dosage forms for them. The notice adds that the five are not marketed internationally as approved drug products.
The notice also cites law-enforcement reports, saying the five have been reported as drugs of abuse in the United States and identified in seizures. Law enforcement first encountered 5-MeO-AMT and DiPT in 2003, 5-MeO-MiPT in 2004, 5-MeO-DET in 2006 and 4-OH-DiPT in 2009.
Poison-center data from 2003 to 2021 show sporadic cases, which the notice says were mostly classified as abuse with minor to moderate outcomes. These are DEA's and HHS's stated findings.
DEA first proposed Schedule I for these five tryptamines on January 14, 2022, and withdrew that proposal on July 27, 2022. The January notice appears in the Federal Register (FR) at 87 FR 2376.
On July 6, 2022, DEA announced a hearing at 87 FR 40167. On July 27, 2022, DEA withdrew both the proposed rule and the hearing notice at 87 FR 45076. The stated reason was a decision to ask HHS for an updated evaluation.
DEA made that request on November 16, 2023, and HHS answered on April 2, 2026. HHS's earlier evaluations and recommendations were from 2012.
The 2026 notice cites the April 2, 2026 HHS evaluation as its basis.
The DEA proposal does not change federal law today, because it is a notice of proposed rulemaking and DEA has not published a final rule. The five substances keep their current federal status until a final rule appears in the Federal Register.
The notice proposes no change for psilocybin, MDMA, ketamine, DMT or 5-MeO-DMT. How those substances are scheduled today is covered on the Controlled Substances Act page. A state-by-state view is in what psychedelics are legal in the US, and other federal and state rules are on the law index.
Dates and text on this page reflect the notice as of October 11, 2026. Confirm the deadline and rule text on regulations.gov and on the Federal Register page for document 2026-19400 before filing.
To file before the deadline, open Docket No. DEA1715 on regulations.gov and submit a comment on the DEA Schedule I tryptamines proposal by 11:59 p.m. Eastern on October 23, 2026.
DEA is proposing to place five tryptamine hallucinogens in Schedule I of the Controlled Substances Act: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT. The proposal includes their salts, isomers and salts of isomers whenever possible. If finalized, Schedule I controls and sanctions would apply to anyone who handles them.
Comments are due on or before October 23, 2026. That is 30 days after the scheduled Federal Register publication date of September 23, 2026. Electronic comments close at 11:59 p.m. Eastern Time on October 23, and paper comments must be postmarked by that date.
Submit it electronically through the Federal eRulemaking Portal at regulations.gov under Docket No. DEA1715, or mail it to Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. Reference Docket No. DEA1715 on all correspondence. DEA discourages sending a paper copy of a comment already filed electronically.
Yes, if the rule is finalized, researchers would need DEA registration to handle the five substances. A researcher already registered for another Schedule I substance and already studying the five may continue if they apply within 90 calendar days after the final rule takes effect, under 21 U.S.C. 822(h). Anyone not registered for Schedule I research would have to apply and could not continue handling the substances until DEA approves.
No, it is a notice of proposed rulemaking. Nothing changes legally until DEA publishes a final rule in the Federal Register. The proposal also makes no change to psilocybin, MDMA, ketamine, DMT or 5-MeO-DMT.
Yes, DEA proposed Schedule I for the same five substances on January 14, 2022, and announced a hearing on July 6, 2022. DEA withdrew the proposal and hearing notice on July 27, 2022, to ask HHS for an updated evaluation. HHS delivered that evaluation on April 2, 2026, again recommending Schedule I.
Get DEA Proposal: Five Tryptamines Into Schedule I updates
New votes, rules, court rulings, and access changes for DEA Proposal: Five Tryptamines Into Schedule I — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.